Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Clinical trial NCT02296112 · COMPLETED

Trial details

NCT number: NCT02296112
Sponsor: Vanderbilt-Ingram Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma

Start date: 2015-01-01
Primary completion: 2018-08-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.